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Abstract Exposure to the industrial solvent, styrene,
induces locomotor and cognitive dysfunction in rats, and
parkinsonian-like manifestations in man. The antipsy-
chotic, haloperidol (HP), well known to induce striatal
toxicity in man and animals, and styrene share a common
metabolic pathway yielding p-ﬂuoro phenylglyoxylic acid
and phenylglyoxylic acid (PGA), respectively. Using an
exposure period of 30 days and the vacous chewing
movement (VCM) model as an expression of striatal-motor
toxicity, we found that incremental PGA dosing
(220–400 mg/kg) signiﬁcantly increased VCMs up to day
25, but decreased to control levels shortly after reaching
maximum dose. However, a diminishing dose of PGA
(400–200 mg/kg) did not evoke an immediate worsening of
VCMs but precipitated a signiﬁcant increase in VCMs
following dosage reduction to 200 mg/kg on day 22. PGA
exposure, therefore, compromises striatal-motor function
that is especially sensitive to changes in exposure dose.
Longer alternating dose exposure studies are needed to
establish whether motor dysfunction is progressive in
severity or longevity. These ﬁndings are of signiﬁcance for
the environmental toxicology of styrene in the chemical
industry.
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Exposure to environmental toxins and chemicals can
increase the risk of developing neurodegenerative diseases,
such as Parkinson’s disease, or parkinsonian-like disorders
(Betarbet et al. 2000). Styrene is extensively used in the
manufacture of various polymers and co-polymers. It is
known, however, that humans (Cherry et al. 1981) and
animals (Chakrabarti 2000) exposed to high levels of sty-
rene present with various neurological symptoms, includ-
ing parkinsonism-like manifestations and progressive
worsening of motor function.
It is believed that phenylglyoxylic acid (PGA), one of
the major metabolites of styrene (Sumner and Fennel
1994), is responsible for the neurotoxic effects of styrene
via its amination product, a-phenylglycine (a-PG; Fig. 1)
leading to depletion of striatal dopamine (DA; Romanelli
et al. 1986). Mienie et al. (1999) reported the presence of
p-ﬂuorophenylglycine (p-FPG) in the urine of baboons
treated with the tetrahydropyridine (HTPT) dehydration
product of the antipsychotic drug, haloperidol (HP), also
demonstrating the pre-requisite inter-conversion of p-ﬂu-
orophenylglyoxylic acid (p-FPGA) to p-FPG (Fig. 1). The
formation of the unﬂuorinated congener of p-FPGA, PGA,
from styrene has been detected in urine, as well as the
aminotransferase product, a-PG (Manini et al. 2002). The
similarities in the metabolic pathways of HP and styrene
(Fig. 1) and the identiﬁcation of the p-ﬂuoro-substituted
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DOI 10.1007/s12640-010-9222-yanalog of HPTP could possibly explain the incidence of
parkinsonian symptoms induced by these compounds.
Although the behavioral manifestation of striatal-motor
toxicity for styrene and HP are known, this has not yet
been fully explored for PGA. Moreover, with recent evi-
dence suggesting that styrene toxicity may more be related
to the parent compound itself and not PGA (Ladefoged
et al. 1998), further conﬁrmation of this assumption is
required.
First generation antipsychotics like HP are well known
to worsen striatal-motor dysfunction after acute and
chronic treatment (Andreassen and Jørgensen 2000), while
dose reduction may also worsen motor symptoms (Anand
and Dewan 1996). Considering this, we have used the
vacuous chewing movement (VCM) model (Andreassen
and Jørgensen 2000), and a dosage escalation and reduction
treatment protocol, to access the striatal-motor toxicity
potential of PGA in rats following chronic (30 days)
exposure.
Adult male Sprague-Dawley rats (180–220 g, ±4
months) were housed four rats/cage at the Animal Research
Centre of North-West University under constant conditions
of temperature (21 ± 1C) and humidity (50 ± 10%), with
a12:12 hlight–dark cycleandfreeaccess tofoodandwater.
The Ethics Committee of the North-West University, Pot-
chefstroom, approved all the procedures performed on the
animals (ethics number NWU-00020-09-S5).
Two groups of rats were treated with daily oral dosages
of PGA (Sigma-Aldrich Chemical Co.,South Africa),
administered at 0800 h each day, for a period of 30 days.
Group 1 animals (study 1) were treated with an initial
dosage of 220 mg/kg body mass PGA, subsequently
increased to 400 mg/kg body mass over the ﬁrst 15 days of
treatment (days 1–4 220 mg/kg; days 5–9 250 mg/kg; days
10–15 350 mg/kg, days 16–30 400 mg/kg), and maintained
as such for the last 15 days of treatment. Group 2 animals
(study 2) were treated with an initial daily oral dose of
400 mg/kg body mass PGA, but which was decreased to
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Fig. 1 Proposed similarities
between haloperidol (or HPTP)
and styrene metabolism (Mienie
et al. 1999), yielding p-ﬂuoro
phenylglyoxylic acid and
phenylglyoxylic acid (PGA),
respectively
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123330 mg/kg on day 17 and to 200 mg/kg on day 20 (days
1–16 400 mg/kg; days 17–19 330 mg/kg; days 20–30
200 mg/kg). The control groups received equivalent vol-
umes of the vehicle only (distilled water). Group 1consisted
of12PGA-treatedand12controlrats,withVCMs scoredon
days 0, 4, 8, 11, 22, 25, and 29. Group 2 consisted of eight
PGA-treatedratsandfourcontrolrats,withVCMsscoredon
days0,5,8, 11,22,26,and 30.Behavioralassessmentswere
carried out in raised transparent cages (34 9 28 9 30 cm
with wire mesh bottom) between 1400 and 1530 h, the time
delay to insure that oral movements observed were not a
result ofirritationfrom the orally administered PGA.Aftera
2-min habituation period, each rat was observed for 2 min
by three trained and treatment-blind observers, with VCMs
graded and quantiﬁed as follows: single chewing move-
ments (a single movement not directed toward an object and
unrelated to grooming, gnawing, or mouthing food); chew
bursts (two or more movements rapidly following one
another); and tongue protrusions, with each of the above
counted as one separate movement (Harvey and Bester
2000). Individual observed scores were tallied for each rat
and expressed as total VCMs/2 min.
The overall effects of PGA on VCMs were analyzed
with a repeated measures analysis of variance (ANOVA).
Differences between control and PGA groups in both
studies were analyzed with a two-way ANOVA with a
ﬁxed effect on grouping and repeated measure factor over
time, followed by analysis of covariance (ANCOVA) to
compare the means of the two groups adjusting for the
baseline value. Due to deviations from normality in group
1, each day’s data was ﬁrst transformed by using the Box–
Cox transformation. In all the cases, data are expressed as
mean ± SEM with P\0.05 deemed signiﬁcant.
A deﬁnite increase in VCMs versus control was observed
as the dose of PGA escalated over time from the start of
treatment (Study 1; Fig. 2), with PGA inducing higher
VCMs already on day 8 of treatment, reaching signiﬁcance
by day 11 (2.33 ± 1.032 vs. 4.50 ± 1.031; F = 4.52;
P = 0.046) and peaking on day 22 (3.75 ± 1.497 vs.
7.67 ± 1.497; F = 5.58; P = 0.044). Interestingly, VCMs
decreased after day 22, i.e. shortly after dose escalation to
400 mg/kg, although was still signiﬁcantly higher than
control on day 25 (2.50 ± 0.906 vs. 6.33 ± 0.906;
F = 9.34; P = 0.005; Fig. 2). On the last day of treatment
(day 30), VCMs associated with PGA had reached equiv-
alence with control (Fig. 2). In the study 2 protocol, we
observed no noteworthy increase in VCMs during the early
stages of PGA treatment when the dose of PGA was highest
(400 mg/kg; Fig. 3). However, VCMs were signiﬁcantly
worse on day 22 compared to control (3.20 ± 1.279 vs.
9.17 ± 0.929; F = 12.31; P = 0.008) following a decrease
in PGA dosage to 330 mg/kg on day 17 and a further
reduction to 200 mg/kg on day 20. A progressive worsening
of VCMs then ensued, with VCMs reaching even higher
levels compared to control on day 26 (0.47 ± 2.151 vs.
13.16 ± 1.548; F = 19.69; P = 0.002) and day 30 (1.66 ±
2.121 vs. 13.19 ± 1.526; F = 16.70; P = 0.004; Fig. 3).
Treatment with PGA at incremental dosages resulted in
a gradual increase in spontaneous VCMs over time to
signiﬁcant levels (Fig. 2). The presence of background
VCM’s observed in control animals is not unusual and is
known to be highly variable in rats (Glenthøj and Hem-
mingsen 1991; Andreassen and Jørgensen 2000). The
worsening of spontaneous VCMs by PGA is not unlike that
seen following treatment with HP (Andreassen and
Jørgensen 2000; Harvey and Bester 2000). In the case of
Study 1
0 5 10 15 20 25 30 35
0
1
2
3
4
5
6
7
8
9
10
11
PGA
Control
Time (days)
A
v
e
r
a
g
e
 
V
C
M
s
/
2
 
m
i
n
*
*
*
220 mg/kg 250 mg/kg  350 mg/kg  400 mg/kg 
Fig. 2 Time course of PGA treatment and the effect of increasing
dosages on the days indicated, on average VCMs in PGA and vehicle
treated rats as determined in Group 1 (mean ± SEM). Day 11 *
P = 0.046, day 22 * P = 0.044, day 25 * P = 0.005 (ANCOVA)
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Fig. 3 Time course of PGA treatment and the effect of decreasing
dosages on the days indicated, on average VCMs in PGA and vehicle
treated rats as determined in Group 2 (mean ± SEM). Day 22 *
P = 0.008, day 26 * P = 0.002, day 30 * P = 0.004 (ANCOVA)
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123HP, this phenomenon has been linked to striatal dopamine
depletion and dopamine receptor hypersensitivity (Andre-
assen and Jørgensen 2000). Indeed, earlier studies in rab-
bits have found that prolonged PGA exposure signiﬁcantly
depletes striatal dopamine (Romanelli et al. 1986), and
which we also have observed in rats following a 30-day
exposure to oral PGA (Terre’Blanche, unpublished obser-
vation). Since both styrene and HP are associated with in
vivo conversion to PGA (Fig. 1), it could be argued that
PGA underlies the striatal toxicity inherent in both styrene
and HP.
Sub-chronic and long-term treatment with HP engenders
a rapid and sustained elevation in VCMs which worsens
following an increase in dose, or sudden discontinuation
(Steinpreis et al. 1997; Andreassen and Jørgensen 2000). In
this study, however, higher dosages of PGA given during
the latter stages of treatment (Group 1, Fig. 2) evoke fewer
VCMs than lower dosages of the compound. Here VCMs
escalated as the dose of PGA increased from 200 to
400 mg/kg over the ﬁrst 3 weeks of treatment, but in the
last week of treatment at maximum dose VCMs gradually
returned to control levels (Fig. 2). This apparent lessening
of motor toxicity in the ﬁnal week of treatment at maxi-
mum dose suggests that PGA-induced striatal toxicity,
unlike that with HP, normalizes at some point, or alterna-
tively is a product of an adaptive phenomenon at another
level of striatal functioning. It is, however, interesting
given the earlier mentioned observation that PGA decrea-
ses striatal dopamine levels, suggesting that a disturbance
in dopamine persists in spite of an apparent improvement
in symptoms.
Interestingly, when we consider more closely the results
from Group 2, initiating PGA treatment at a starting dose
of 400 mg/kg and sustained over the ﬁrst 16 days of
treatment was not associated with an expected exacerbation
of VCMs (Fig. 3), also unlike that seen with HP (Andre-
assen and Jørgensen 2000). In fact, VCMs increased rap-
idly only after the dosage was reduced to 330 mg/kg (on
day 17) and then to 200 mg/kg (on day 20; Fig. 3).
Together these data suggest an increased sensitivity to
developing striatal-motor dysfunction following variations
in daily/weekly PGA exposure. Changes in motor function
after dose escalation and/or reduction are also noted with
ﬁrst generation antipsychotics (Anand and Dewan 1996;
Andreassen and Jørgensen 2000).
Considering the continued awareness of the potential of
styrene as an environmental toxin (Seeber et al. 2009), this
study provides new evidence concerning the striatal-motor
toxicity of PGA, one of the major metabolites of styrene.
We have demonstrated that rats treated orally with
increasing dosages of PGA over a period of 30 days, as is
typically observed with HP, is associated with a signiﬁcant
worsening of VCMs, suggestive of striatal-motor toxicity.
However, unlike HP these behaviors are transient as VCMs
returned to control values later on in treatment. Impor-
tantly, initial high dosages of PGA did not worsen VCMs,
yet later on dosage reduction signiﬁcantly exacerbated
VCMs. Thus, PGA exposure distinctly compromises stri-
atal-motor function that may be especially sensitive to
week-by-week changes in exposure dose. However, our
data suggest that these effects are not progressive in
severity or longevity after dose escalation, possibly sup-
portive of earlier studies that have failed to implicate PGA
in the long-term neurotoxic effects of styrene (Ladefoged
et al. 1998), although may not apply to dose reduction. This
would, by implication, apply to its possible role in HP
toxicity as well. Consequently, longer alternating dose
exposure studies with PGA are needed to shed more light
on whether its apparent benign proﬁle remains transient,
whether striatal-motor function worsens over time, and
whether striatal neurotransmitters are affected in any way.
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